Twist Bioscience Corp (TWST) - Net Assets
Based on the latest financial reports, Twist Bioscience Corp (TWST) has net assets worth $455.09 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($676.21 Million) and total liabilities ($221.12 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Twist Bioscience Corp (TWST) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $455.09 Million |
| % of Total Assets | 67.3% |
| Annual Growth Rate | N/A |
| 5-Year Change | -18.57% |
| 10-Year Change | N/A |
| Growth Volatility | 52.59 |
Twist Bioscience Corp - Net Assets Trend (2016–2025)
This chart illustrates how Twist Bioscience Corp's net assets have evolved over time, based on quarterly financial data. See TWST days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Twist Bioscience Corp (2016–2025)
The table below shows the annual net assets of Twist Bioscience Corp from 2016 to 2025. For live valuation and market cap data, see TWST market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $472.96 Million | +0.06% |
| 2024-09-30 | $472.69 Million | -24.18% |
| 2023-09-30 | $623.43 Million | -21.02% |
| 2022-09-30 | $789.38 Million | +35.91% |
| 2021-09-30 | $580.82 Million | +72.73% |
| 2020-09-30 | $336.26 Million | +121.11% |
| 2019-09-30 | $152.08 Million | +175.50% |
| 2018-09-30 | $-201.42 Million | -51.04% |
| 2017-09-30 | $-133.36 Million | -74.07% |
| 2016-09-30 | $-76.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Twist Bioscience Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 123926900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $-627.00K | -0.13% |
| Other Components | $1.79 Billion | 379.14% |
| Total Equity | $472.96 Million | 100.00% |
Twist Bioscience Corp Competitors by Market Cap
The table below lists competitors of Twist Bioscience Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Silicon Motion Technology
NASDAQ:SIMO
|
$4.32 Billion |
|
Bluestar Adisseo Co
SHG:600299
|
$4.32 Billion |
|
Shan XI Hua Yang Group New Energy Co Ltd
SHG:600348
|
$4.32 Billion |
|
Grupo Aeroportuario del Centro Norte S.A.B. de C.V.
F:G7A
|
$4.32 Billion |
|
Benefit Systems SA
WAR:BFT
|
$4.31 Billion |
|
LEG Immobilien SE
XETRA:LEG
|
$4.31 Billion |
|
Xiamen Kehua Hengsheng
SHE:002335
|
$4.31 Billion |
|
Xi an Bright Laser Tech Co Ltd
SHG:688333
|
$4.31 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Twist Bioscience Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 472,689,000 to 472,958,000, a change of 269,000 (0.1%).
- Net loss of 77,670,000 reduced equity.
- Share repurchases of 16,000 reduced equity.
- Other comprehensive income decreased equity by 105,000.
- Other factors increased equity by 78,060,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-77.67 Million | -16.42% |
| Share Repurchases | $16.00K | -0.0% |
| Other Comprehensive Income | $-105.00K | -0.02% |
| Other Changes | $78.06 Million | +16.5% |
| Total Change | $- | 0.06% |
Book Value vs Market Value Analysis
This analysis compares Twist Bioscience Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.07x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-09-30 | $-4.08 | $87.56 | x |
| 2017-09-30 | $-7.10 | $87.56 | x |
| 2018-09-30 | $-7.57 | $87.56 | x |
| 2019-09-30 | $5.54 | $87.56 | x |
| 2020-09-30 | $8.58 | $87.56 | x |
| 2021-09-30 | $12.04 | $87.56 | x |
| 2022-09-30 | $14.65 | $87.56 | x |
| 2023-09-30 | $10.96 | $87.56 | x |
| 2024-09-30 | $8.15 | $87.56 | x |
| 2025-09-30 | $7.91 | $87.56 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Twist Bioscience Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -16.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -20.63%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 1.36x
- Recent ROE (-16.42%) is above the historical average (-25.96%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | -1943.06% | 0.03x | 0.00x | $-36.43 Million |
| 2017 | 0.00% | -550.85% | 0.13x | 0.00x | $-45.97 Million |
| 2018 | 0.00% | -280.16% | 0.22x | 0.00x | $-51.09 Million |
| 2019 | -70.80% | -197.98% | 0.29x | 1.23x | $-122.88 Million |
| 2020 | -41.61% | -155.31% | 0.23x | 1.19x | $-173.56 Million |
| 2021 | -26.19% | -114.94% | 0.19x | 1.21x | $-210.18 Million |
| 2022 | -27.60% | -107.02% | 0.21x | 1.22x | $-296.80 Million |
| 2023 | -32.82% | -83.48% | 0.32x | 1.25x | $-266.96 Million |
| 2024 | -44.16% | -66.69% | 0.51x | 1.30x | $-255.99 Million |
| 2025 | -16.42% | -20.63% | 0.59x | 1.36x | $-124.97 Million |
Industry Comparison
This section compares Twist Bioscience Corp's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $655,728,646
- Average return on equity (ROE) among peers: -117.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Twist Bioscience Corp (TWST) | $455.09 Million | 0.00% | 0.49x | $4.31 Billion |
| Agilent Technologies Inc (A) | $4.63 Billion | -22.30% | 0.77x | $35.96 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $976.24K | -188.19% | 0.03x | $6.13 Million |
| Applied DNA Sciences Inc (APDN) | $8.97 Million | -77.97% | 0.43x | $3.99 Million |
| Biodesix Inc (BDSX) | $20.88 Million | -205.65% | 3.66x | $79.44 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.07 Million | 0.00% | 0.00x | $3.77 Million |
| Biocept Inc. (BIOCQ) | $8.86 Million | -362.16% | 2.48x | $525.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $480.11 Million | 1.55% | 0.32x | $4.36 Billion |
| Burning Rock Biotech Ltd (BNR) | $1.16 Billion | -83.85% | 0.37x | $63.90 Million |
| CareDx Inc (CDNA) | $261.33 Million | -72.81% | 0.79x | $1.13 Billion |
| Check Cap Ltd (CHEK) | $5.91 Million | -165.47% | 0.34x | $9.42 Million |
About Twist Bioscience Corp
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo … Read more